EXECUTIVE ENGAGEMENTS
POOL
2183
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
393
Interactions with Platform & by Email
PARTICIPANTS
66
Unique # Participated
VALIDATIONS
22
Responses Validated*
COMPANIES
56
Responses Validated*
* Login for a full stack data experience
DATE
OCT 2022
TABLES
122
PAGES
202
EDITION
19
PRICE
USD 5600
CODE
MCP-7815
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
What`s New for 2023?
» Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Looking Ahead to 2023
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Amid the COVID-19 crisis, the global market for Mesenchymal Stem Cells (MSC) estimated at US$3 Billion in the year 2020, is projected to reach a revised size of US$6.5 Billion by 2027, growing at a CAGR of 12% over the analysis period 2020-2027. Bone Marrow, one of the segments analyzed in the report, is projected to record a 13.1% CAGR and reach US$2.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Adipose Tissues segment is readjusted to a revised 14.8% CAGR for the next 7-year period.
The Mesenchymal Stem Cells (MSC) market in the U.S. is estimated at US$868.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2027 trailing a CAGR of 11.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.2% and 10% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.
In the global Fetal Liver segment, USA, Canada, Japan, China and Europe will drive the 11.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$385.9 Million in the year 2020 will reach a projected size of US$810.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$770.3 Million by the year 2027.
SELECT PLAYERS
Cell Applications Inc.; Celprogen Inc.; Cyagen US Inc.; Genlantis Inc.; Lonza Group; Mesoblast Limited; MilliporeSigma; Neuromics; Orthofix International N.V.; PromoCell GmbH; R&D Systems Inc.; ScienCell Research Laboratories; Stemcell Technologies Inc.; Stemedica Cell Technologies Inc.; Thermo Fischer Scientific Inc.
SEGMENTS
» Source of MSC Isolation (Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood, Other Sources of MSC Isolation) » Application (Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies, Other Applications)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Mesenchymal Stem Cells Market on a Rapid Growth Path |
| Recent Market Activity |
| Current and Future Analysis |
| The Present and Future of MSC Therapies |
| Select MSC-based Therapeutics |
| Mesenchymal Stem Cell Research |
| Completed Phase III Studies with MSCs |
| MSCs are Being Explored for Several New Treatment Possibilities |
| Widespread Commercialization of 'Off-the-Shelf' MSCs to Become a Reality |
| Software Companies Endeavour to Cash in on the Boom |
| Mesenchymal Stem Cells (MSC) – Global Key Competitors Percentage Market Share in 2022 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| Cell Applications, Inc. (USA) |
| Celprogen, Inc. (USA) |
| Cyagen US Inc. (USA) |
| Genlantis, Inc. (USA) |
| Lonza Group (Switzerland) |
| Mesoblast Limited (Australia) |
| MilliporeSigma (USA) |
| Neuromics (USA) |
| Orthofix International N.V. (Italy) |
| PromoCell GmbH (Germany) |
| R&D Systems, Inc. (USA) |
| ScienCell Research Laboratories (USA) |
| Stemcell Technologies Inc. (Canada) |
| Stemedica Cell Technologies, Inc. (USA) |
| Thermo Fischer Scientific, Inc. (USA) |
| Vitro Biopharma (USA) |
| 3. MARKET TRENDS & DRIVERS |
| Development of Regenerative Medicine Accelerates Demand for MSCs |
| Ageing Demographics to Drive Demand for Mesenchymal Stem Cell Therapies |
| Global Aging Population Statistics - Opportunity Indicators |
| Growing Prevalence of Chronic Diseases Propels Demand for Mesenchymal Stem Cells |
| Key Disease Statistics - Opportunity Indicators |
| Growing Volume of Orthopedic Procedures: An Opportunity for the MSC Market |
| Adult Stem Cell Therapies on Growth Trajectory, as Controversies Continue to Haunt Embryonic Stem Cell Research |
| Adult Stem Cells and Embryonic Stem Cells - A Comparison |
| MSCs Versus Embryonic or Induced Pluripotent Stem Cells |
| MSC Therapies - Immune to Ethical Issues Applicable to Embryonic Stem Cells |
| MSCs - A Potential Vehicle for 'Targeted Drug Delivery' |
| Stem Cell Based Bone Grafts: Promising Growth Ahead |
| Loopholes Associated with In Vivo Properties Constrain Therapeutic Advancements |
| Major Challenges Confronting Mesenchymal Stem Cell Market |
| Allogeneic MSCs - Offering Promise in Immunosuppressive and Tissue Repair Therapy |
| Administration Route Determines the Effectiveness of MSCs |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Mesenchymal Stem Cells (MSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Bone Marrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Adipose Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Adipose Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Adipose Tissues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Fetal Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Fetal Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Fetal Liver by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Lung by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cord Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Other Sources of MSC Isolation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Sources of MSC Isolation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Sources of MSC Isolation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Disease Modelling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Disease Modelling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Disease Modelling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Drug Development & Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Drug Development & Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Drug Development & Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Stem Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Stem Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Stem Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Tissue Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Toxicology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Toxicology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Toxicology Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Mesenchymal Stem Cells (MSC) Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
| USA Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2012, 2021 & 2027 |
| USA Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2012, 2021 & 2027 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2012, 2021 & 2027 |
| Canada Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2012, 2021 & 2027 |
| JAPAN |
| Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
| Japan Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2012, 2021 & 2027 |
| Japan Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2012, 2021 & 2027 |
| CHINA |
| Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
| China Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2012, 2021 & 2027 |
| China Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2012, 2021 & 2027 |
| EUROPE |
| Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
| Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Mesenchymal Stem Cells (MSC) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2012, 2021 & 2027 |
| FRANCE |
| Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
| France Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2012, 2021 & 2027 |
| France Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2012, 2021 & 2027 |
| GERMANY |
| Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
| Germany Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2012, 2021 & 2027 |
| Germany Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2012, 2021 & 2027 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2012, 2021 & 2027 |
| Italy Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2012, 2021 & 2027 |
| UNITED KINGDOM |
| Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
| UK Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2012, 2021 & 2027 |
| UK Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2012, 2021 & 2027 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2012, 2021 & 2027 |
| Rest of Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2012, 2021 & 2027 |
| ASIA-PACIFIC |
| Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2012, 2021 & 2027 |
| Asia-Pacific Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2012, 2021 & 2027 |
| REST OF WORLD |
| Rest of World Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2012, 2021 & 2027 |
| Rest of World Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2012, 2021 & 2027 |
| IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com